|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 9S. Outcome and EBOV Genome Equivalents in Plasma and CSF from Experiment 3** | | | | | | | | | |
| Group | Animal ID | *In vivo* outcome (day) | Plasma EBOV (GE/mL) by study day | | | | | | CSF at necropsy (GE/mL) |
| 3 | 5 | 6 | 7 | 8 | 9 |
| Saline control | 1 | D7 | <LOQ | 1.7E9 | NT | 6.5E10 | NT | NT | 4.2E7 |
| 10 | D7 | <LOQ | 3.7E8 | NT | 2.8E10 | NT | NT | 5.2E7 |
| 4 | D7 | <LOQ | 2.1E9 | NT | 7.9E10 | NT | NT | 2.2E7 |
| 3 | D8 | <LOQ | 9.5E7 | NT | 9.1E9 | 4.0E9 | NT | 2.7E7 |
| LI: Irrelevant Tc hIgG control | 12 | D8 | <LOQ | 1.8E9 | NT | 3.6E10 | 1.4E10 | NT | 4.6E7 |
| 9 | D7 | <LOQ | 3.2E8 | NT | 6.5E10 | NT | NT | 8.8E7 |
| LI: SAB-139/ V6-V8 | 5 | D7 | <LOQ | 5.1E9 | NT | 5.7E10 | NT | NT | 8.8E8 |
| 7 | D9 | <LOQ | 1.8E8 | NT | 1.1E8 | NT | 1.4E9 | 1.4E8 |
| 11 | D7 | 3.7E5 | 3.5E10 | NT | 8.2E10 | NT | NT | 2.3E7 |
| 8 | D6 | <LOQ | 4.3E9 | 1.5E10 | NT | NT | NT | <LOQ |
| 2 | D7 | <LOQ | 7.7E9 | NT | 3.2E10 | NT | NT | 2.0E6 |
| 6 | D9 | <LOQ | 2.6E8 | NT | 3.3E8 | NT | 2.9E9 | 1.7E9 |

Abbreviations: D, died (day); EI, early intervention (treatment initiated on day 1 postexposure); GE, genome equivalents; ID, identification number; LI, late intervention (treatment initiated on day 5 postexposure); LOQ, limit of quantification; NT, not tested; S, survived; Tc hIgG, transchromosomic human Imunolglobulin G.